Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval

Novartis and PTC Advance Votoplam to Phase 3 for Huntington's Disease

Novartis and PTC Therapeutics are advancing their Huntington's disease candidate, votoplam, into a Phase 3 trial (INVEST-HD) following encouraging interim data from the long-term extension of the mid-stage PIVOT-HD study. The 5-mg dose of votoplam slowed disease progression by 28% at 24 months, while the 10-mg dose reduced worsening by 52% compared to natural history controls. The decision to proceed to Phase 3, which will enroll 770 patients and is expected to read out in 2030, suggests confidence in the program but also apprehension regarding the likelihood of accelerated FDA approval based on existing data. Novartis will lead the late-stage development, while PTC will collaborate on regulatory discussions.

• Interim results from the PIVOT-HD long-term extension phase demonstrated votoplam's efficacy in slowing Huntington's disease progression. The 5-mg dose showed a 28% reduction in worsening at 24 months, while the 10-mg dose achieved a 52% reduction compared to natural history controls. Additionally, prolonged votoplam treatment successfully maintained neurofilament light chain levels below baseline throughout the 24-month follow-up period, indicating a sustained biological effect.
• Following these positive mid-stage data, Novartis has launched the Phase 3 INVEST-HD study for votoplam. This late-stage trial will evaluate the drug against placebo in 770 patients with Huntington's disease, with a readout anticipated in 2030. Analysts suggest that while this advancement conveys long-term optimism, the partners' measured approach to regulatory plans, without specific mention of accelerated approval, indicates a view that the current dataset may not be wholly conclusive for an expedited FDA nod.
• The development of votoplam is governed by a partnership established in December 2024, where Novartis partnered with PTC Therapeutics. The agreement included a $1 billion upfront payment and up to $1.9 billion in potential milestones. Under the terms, PTC was responsible for the PIVOT-HD study, after which Novartis assumed leadership for the late-stage program. PTC retains a 40% share of votoplam's U.S. profits and is eligible for double-digit tiered royalties on international sales.

Votoplam's Phase 2 Data and the Unmet Need in Huntington's Disease

Over the past three years, Huntington's disease research has identified significant treatment gaps and underserved populations that represent critical areas for therapeutic development. Despite substantial research investments, HD remains without a cure or disease-modifying therapy, highlighting the urgent need for innovative approaches to address this devastating neurodegenerative disorder.

• Absence of Disease-Modifying Therapies: No cure or effective disease-modifying treatments currently exist for HD, with available therapies only targeting symptom management rather than altering disease progression. Current treatments primarily focus on reducing chorea symptoms and offer limited benefits, while drug candidates targeting single molecular targets have consistently failed to demonstrate significant therapeutic success.

• Healthcare Access and Care Coordination Barriers: Significant disparities exist in care delivery, with 70.8% of patients reporting inappropriate overall HD care due to long delays accessing medical services and healthcare teams. Geographic barriers, transportation costs, and limited service availability create substantial obstacles to quality care, while only 19% of patients have access to care coordinators despite 58% rating this as extremely important.

• Underserved Global Populations: The MENAT region (Middle East, North Africa, and Turkey) shows dramatically underreported HD prevalence at 0.17 per 100,000 compared to global estimates, likely reflecting underdiagnosis and limited genetic testing capacity. Several Asian countries also demonstrate lower prevalence rates, with social stigma, marriage concerns, and lack of genetic testing infrastructure preventing proper diagnosis and care.

• COVID-19 Impact on Disease Management: The pandemic severely disrupted HD care, with 48% of patients experiencing worsening pre-existing symptoms and 44% developing new-onset symptoms, particularly affecting gait and balance (67%), fatigue (58%), anxiety (50%), and depression (50%). Additionally, 54.2% reported negative impacts on caregivers and family members.

• Racial and Socioeconomic Healthcare Disparities: Black participants in North America present with more advanced disease than White patients, while individuals with less than high school education enter clinical studies with lower functional capacity scores. These disparities highlight the need to address social and structural determinants of health in historically marginalized communities.

• Novel Therapeutic Target Development: Research focus has shifted toward multi-target approaches, immunotherapies, and innovative delivery systems including cell replacement therapy, gene editing technologies, and nanoparticle-based treatments. Specific targets include MSH3 for somatic CAG repeat expansion, PGC-1α for mitochondrial dysfunction, and ubiquitin-proteasome system modulation for protein aggregation management.

Designing the Pivotal INVEST-HD Trial for Votoplam in Huntington's Disease

Several pivotal trials have established important design frameworks for Huntington's disease clinical research, ranging from symptomatic treatments to disease-modifying approaches. These studies demonstrate evolving endpoints and methodological considerations that inform current trial design for novel therapeutics like votoplam.

Key Biomarker Categories for Endpoints:

• Neuroimaging: Caudate and putamen volumetrics (best validated for pre-manifest phase); structural MRI showing progressive striatal and cortical atrophy

• Biofluid: CSF neurofilament light chain and mutant huntingtin as disease progression indicators

• Functional: UHDRS motor scores, cognitive assessments, quality of life measures

• Physical Performance: Berg Balance Scale, Physical Performance Test, and Timed "Up & Go" Test show optimal reliability and sensitivity for manifest HD trials

Votoplam's Phase 3: A Measured Advance in Huntington's Disease

The decision to advance votoplam (PTC518) into a pivotal Phase 3 trial for Huntington's disease (HD) represents a significant, albeit cautious, step forward in the quest for effective treatments for this devastating neurodegenerative condition. With no approved disease-modifying therapies currently available, the high unmet medical need in HD makes any progress in this space critically important. Votoplam, an orally administered huntingtin (HTT) pre-mRNA splicing modifier, has demonstrated a proof of mechanism by reducing HTT mRNA and protein levels in early studies. The interim Phase 2 data, showing a dose-dependent slowing of disease progression by up to 52% over 24 months compared to natural history, provides encouraging signals of clinical benefit.

However, the path forward is not without its complexities. The class of HTT splicing modifiers has faced challenges, notably the early termination of branaplam's Phase 2b trial due to a high incidence of peripheral neurotoxicity. This underscores the critical need for rigorous safety monitoring in votoplam's large-scale Phase 3 study, potentially leveraging biomarkers like neurofilament light chain (NfL) to detect nerve injury early. While the interim efficacy data is promising, its comparison to natural history controls means the true magnitude of benefit in a placebo-controlled setting remains to be definitively established.

Furthermore, the projected 2030 readout for the INVEST-HD trial highlights the extended timelines typical for neurodegenerative drug development. This long horizon creates a dynamic competitive landscape, with other investigational therapies, including gene therapies and small molecules, progressing through various clinical stages. Novartis's leadership in the Phase 3 development, coupled with PTC's regulatory collaboration, reflects a strategic partnership designed to navigate these challenges. Ultimately, votoplam's journey to market will depend on demonstrating a favorable benefit-risk profile in a large patient population, offering a much-needed therapeutic option for individuals living with Huntington's disease.